#2123102
Miyarisan Pharmaceutical Co. Ltd atá á ionadú ag Huvepharma NV Belgium
Miyarisan Pharmaceutical Co. Ltd represented by Huvepharma NV Belgium
Filter results
Collections
20 results in 10 documents
#3071243
Pharmaceutical Management Agency (Note 17)
Pharmaceutical Management Agency (Note 17);
#1040426
—(1) Leasaítear leis seo alt 32 den Phríomh-Acht trí “or registered under the Pharmacy Act, 1951, as a dispensing chemist and druggist” a chur isteach i ndiaidh “registered under this Act as a pharmaceutical chemist”, “or dispensing chemist and druggist” a chur i ndiaidh “such pharmaceutical chemist” agus “or a dispensing chemist and druggist registered as such under the Pharmacy Act, 1951” a chur i ndiaidh “registered as such under this Act”.
—(1) Section 32 of the Principal Act is hereby amended by inserting "or registered under the Pharmacy Act, 1951 , as a dispensing chemist and druggist" after "registered under this Act a pharmaceutical chemist" "or dispensing chemist and druggist after "such pharmaceutical chemist" and "or a dispensing chemist and druggist registered as such under the Pharmacy Act, 1951 after "registered as such under this Act".
#1040432
(4) Leasaítear leis seo alt 17 d'Acht 1890 trí “or registered dispensing chemist and druggist” a chur isteach i ndiaidh “registered druggist” agus i ndiaidh “duly qualified pharmaceutical chemist”.
(4) Section 17 of the Act of 1890 is hereby amended by inserting "or registered dispensing chemist and druggist" after" registered druggist" and after "duly qualified pharmaceutical chemist".
#1040434
(5) Leasaítear leis seo alt 19 d'Acht 1890 trí “or of a registered dispensing chemist and druggist” a chur isteach i ndiaidh “licentiate of the Pharmaceutical Society”.
(5) Section 19 of the Act of 1890 is hereby amended by inserting "or of a registered dispensing chemist and druggist" after "licentiate of the Pharmaceutical Society".
#1939660
Northeast Pharmaceutical Group Import And Export Trade Co., Ltd., China Jiangsu International Economic And Technical Cooperation Group Co., Ltd. agus Zhejiang Chemicals Import & Export Corporation,
Northeast Pharmaceutical Group Import And Export Trade Co., Ltd, China Jiangsu International Economic And Technical Cooperation Group Co., Ltd and Zhejiang Chemicals Import & Export Corporation,
#2528656
Cuirtear ar fáil i sampla alt a d’fhoilsigh údarás an cheantair Jianan, maidir le Crios Náisiúnta Forbartha Eacnamaíoch agus Teicneolaíochta Xuchang: ‘Chuaigh Rúnaí Choiste an Pháirtí Bhardasaigh go dtí Crios Náisiúnta Forbartha Eacnamaíoch agus Teicneolaíochta Xuchang chun scrúdú a dhéanamh ar thógáil príomhthionscadal […] D’fhiosraigh sé go mionsonraithe orduithe, soláthar páirteanna, etc. […] Ag láithreán tionscadail Ruida Food Additives Co., Ltd., áit a ndéantar 15000 tona cioglamáite sóidiam gach bliain, mhol infheisteoirí de chuid Tianjin Pharmaceutical Group Xuchang arís agus arís eile as a dhea-thimpeallacht ghnó. Chuir Rúnaí Choiste an Pháirtí Bhardasaigh in iúl go raibh súil aige go neartódh Tianjin Pharmaceutical Group a mhuinín infheistíochta agus go nglacfadh sé Xuchang mar phointe tacaíochta. Mar cheirtleán ardmhonaraíochta agus mar phol fáis eacnamaíoch réigiúnach, ní mór do Chrios Náisiúnta Forbartha Eacnamaíoch agus Teicneolaíochta Xuchang smaoineamh eacnamaíoch Xi Jinping maidir le ré nua na heacnamaíochta sóisialaí a bhfuil saintréithe Síneacha aici a chur chun feidhme go cuimsitheach, an coincheap forbartha nua a chur chun feidhme go hiomlán agus go cruinn, a bheith stuama ciallmhar an t-am ar fad, agus feabhas a chur ar an mbraistint freagrachta agus géarchéime.
An example provides an article published by the administration of the Jianan district, concerning the National Xuchang Economic and Technological Development Zone: ‘The Secretary of the Municipal Party Committee, went to the National Xuchang Economic and Technological Development Zone to investigate the construction of key projects […] [He] inquired in detail about orders, parts procurement, etc. […] At the project site of Ruida Food Additives Co., Ltd. with an annual output of 15000 tons of sodium cyclamate, investors from Tianjin Pharmaceutical Group (SOE) repeatedly praised Xuchang for its good business environment. [The Secretary of the Municipal Party Committee] expressed the hope that Tianjin Pharmaceutical Group will strengthen its investment confidence and take Xuchang as the supporting point. […] As an advanced manufacturing agglomeration area and a regional economic growth pole, the National Xuchang Economic and Technological Development Zone must thoroughly implement Xi Jinping’s economic thought for a new era of socialist economic with Chinese characteristics, fully and accurately implement the new development concept, keep a clear head at all times, and enhance the sense of responsibility and crisis.
#2632912
Breithiúnais na Cúirte Breithiúnais an 25.3.2021, C-586/16 P, Sun Pharmaceutical Industries agus Ranbaxy (RA) v an Coimisiún , EU:C:2021:241;
Judgments of the Court of Justice of 25.3.2021, C-586/16 P, Sun Pharmaceutical Industries and Ranbaxy (UK) v Commission, EU:C:2021:241;
#3071266
Pharmaceutical Management Agency: Ar mhaithe le cinnteacht níos fearr, ní chumhdaítear gníomhaíochtaí a bhaineann le feidhmeanna na gníomhaireachta sin i ndáil le cógaisíocht agus feistí leighis a mhaoiniú.
Pharmaceutical Management Agency: For greater certainty, activities related to this agency's functions in respect of funding pharmaceuticals and medical devices is not covered.
#1939093
Faoi mar a chuir an t-iarratasóir isteach, déanann ceann eile de na trí tháirgeoir mhóra aigéid shulfainiligh sa tSín – Hebei Honggang Chemical Industry Co., Ltd – aigéad sulfainileach a onnmhairiú trí dhá chuideachta thrádála ar a laghad atá faoi úinéireacht an Stáit (Northeast Pharmaceutical Group Import and Export Trade Co., Ltd. agus China Jiangsu International Economic and Technical Cooperation Group Co., Ltd).
As submitted by the applicant, another of the three large Chinese producers of sulphanilic acid – Hebei Honggang Chemical Industry Co., Ltd – exports sulphanilic acid through at least two state owned trading companies (Northeast Pharmaceutical Group Import and Export Trade Co., Ltd and China Jiangsu International Economic and Technical Cooperation Group Co., Ltd).
#1939128
Maíonn ceann eile d’onnmhaireoirí móra an aigéid shulfainiligh a luadh níos túisce – Northeast Pharmaceutical Group Import and Export Trade Co., Ltd. – go bhfuil “éisteacht le focail an Uachtaráin Xi, agus an Páirtí a leanúint” ar cheann dá bheartais chorparáideacha agus go bhfuil “Ní mór do reáchtáil gnó a bheith tairbheach don rialtas” ar cheann dá luachanna corparáideacha.
Another of the large exporters of sulphanilic acid mentioned earlier – Northeast Pharmaceutical Group Import and Export Trade Co., Ltd – claims that one of its corporate polices is to ‘Listen to President Xi’s words, and follow the Party’ and that one of its corporate values is ‘Running a business must be beneficial to the government’.
#2068074
An 20 Eanáir 2014, chuir an chuideachta Yakult Pharmaceutical Industry Co., Ltd. in iúl don Choimisiún, de bhun Airteagal 5 den Rialachán (CE) Uimh. 258/97 ó Pharlaimint na hEorpa agus ón gComhairle, go raibh sé ar intinn aici “galachta-olagaisiúcríd” a chur ar an margadh mar bhia núíosach a mbainfear úsáid aisti i roinnt bianna, lena n-áirítear bainne foirmle do naíonáin agus bainne foirmle leantach do naíonáin mar a shainmhínítear i Rialachán (AE) Uimh. 609/2013 ó Pharlaimint na hEorpa agus ón gComhairle.
On 20 January 2014, the company Yakult Pharmaceutical Industry Co., Ltd. informed the Commission, pursuant to Article 5 of Regulation (EC) No 258/97 of the European Parliament and of the Council, of its intention to place on the market ‘galacto-oligosaccharide’ as a novel food to be used in a number of foods, including infant formula and follow-on formula as defined in Regulation (EU) No 609/2013 of the European Parliament and of the Council.
#2068076
An 3 Márta 2020, chuir an chuideachta Yakult Pharmaceutical Industry Co., Ltd. (“an t-iarratasóir”) iarratas faoi bhráid an Choimisiúin i gcomhréir le hAirteagal 10(1) de Rialachán (AE) 2015/2283 chun coinníollacha úsáide an bhia núíosaigh “galachta-olagaisiúcríd” a athrú.
On 3 March 2020, the company Yakult Pharmaceutical Industry Co., Ltd. (‘the applicant’) submitted an application to the Commission pursuant to Article 10(1) of Regulation (EU) 2015/2283 to change the conditions of use of the novel food ‘galacto-oligosaccharide’.
#2123055
maidir le hathnuachan a dhéanamh ar údarú Clostridium butyricum FERM BP-2789 mar bhreiseán bheathaithe le haghaidh sicíní a thógtar le bheith ina mbéaróg, turcaithe lena ramhrú, turcaithe a thógtar le haghaidh pórúcháin, mionspeicis éanúla eile (seachas éin ubh-bhreithe), bainbh scoite agus mionspeicis mhucúla scoite, an t-údarú maidir le sicíní lena ramhrú, bainbh diúil agus mionspeicis mhucúla diúil, agus lena n-aisghairtear Rialacháin Cur Chun Feidhme (AE) Uimh. 373/2011, (AE) Uimh. 374/2013 agus (AE) Uimh. 1108/2014 (sealbhóir an údaraithe Miyarisan Pharmaceutical Co. Ltd atá á ionadú ag Huvepharma NV Belgium)
concerning the renewal of the authorisation of Clostridium butyricum FERM BP-2789 as a feed additive for chickens reared for laying, turkeys for fattening, turkeys reared for breeding, minor avian species (excluding laying birds), weaned piglets and weaned minor porcine species, its authorisation for chickens for fattening, suckling piglets and suckling minor porcine species, and repealing Implementing Regulations (EU) No 373/2011, (EU) No 374/2013 and (EU) No 1108/2014 (holder of authorisation Miyarisan Pharmaceutical Co. Ltd represented by Huvepharma NV Belgium)
#2123087
Rialachán Cur Chun Feidhme (AE) Uimh. 374/2013 ón gCoimisiún an 23 Aibreán 2013 maidir le húdarú ullmhóid Clostridium butyricum (FERM-BP 2789) mar bhreiseán beathaithe le haghaidh sicíní a thógtar le bheith ina mbéaróg (sealbhóir an údaraithe Miyarisan Pharmaceutical Co. Ltd atá á ionadú ag Huvepharma NV Belgium (IO L 112, 24.4.2013, lch. 13).
Commission Implementing Regulation (EU) No 374/2013 of 23 April 2013 concerning the authorisation of a preparation of Clostridium butyricum (FERM-BP 2789) as a feed additive for chickens reared for laying (holder of authorisation Miyarisan Pharmaceutical Co. Ltd represented by Huvepharma NV Belgium (OJ L 112, 24.4.2013, p. 13).
#2123088
Rialachán Cur Chun Feidhme (AE) Uimh. 1108/2014 ón gCoimisiún an 20 Deireadh Fómhair 2014 maidir le húdarú ullmhóid Clostridium butyricum (FERM-BP 2789) mar bhreiseán beathaithe le haghaidh turcaithe lena ramhrú agus turcaithe a thógtar le haghaidh pórúcháin (sealbhóir an údaraithe Miyarisan Pharmaceutical Co. Ltd atá á ionadú ag Huvepharma NV Belgium (IO L 301, 21.10.2014, lch. 16).
Commission Implementing Regulation (EU) No 1108/2014 of 20 October 2014 concerning the authorisation of a preparation of Clostridium butyricum (FERM-BP 2789) as a feed additive for turkeys for fattening and turkeys reared for breeding (holder of authorisation Miyarisan Pharmaceutical Co. Ltd represented by Huvepharma NV Belgium (OJ L 301, 21.10.2014, p. 16).
#2291884
Mar a fógraíodh sa teachtaireacht ón gCoimisiún an 25 Samhain 2020 dar teideal “Pharmaceutical Strategy for Europe” [Straitéis Chógaisíochta don Eoraip], molfaidh an Coimisiún athbhreithniú a dhéanamh ar an reachtaíocht chógaisíochta chun feabhas a chur ar shlándáil an tsoláthair agus chun aghaidh a thabhairt ar ghanntanais táirgí íocshláinte trí bhearta sonracha.
As announced in the communication of the Commission of 25 November 2020 entitled ‘Pharmaceutical Strategy for Europe’, the Commission will propose to revise the pharmaceutical legislation to enhance the security of supply and address shortages of medicinal products through specific measures.
#2336813
Tuarascáil ón gComhlacht Achomhairc, United States – Continued Existence and Application of Zeroing Methodology, WT/DS350/AB/R, glactha an 19 Feabhra 2009, DSR 2009:III, lch. 1291, míreanna 268 agus Tuarascáil ón gComhlacht Achomhairc, India – Patent Protection for Pharmaceutical and Agricultural Chemical Products, WT/DS50/AB/R, glactha an 16 Eanáir 1998, DSR 1998:I, lch. 9, mír 45.
Appellate Body Report, United States – Continued Existence and Application of Zeroing Methodology, WT/DS350/AB/R, adopted 19 February 2009, DSR 2009:III, p. 1291, para. 268 and Appellate Body Report, India – Patent Protection for Pharmaceutical and Agricultural Chemical Products, WT/DS50/AB/R, adopted 16 January 1998, DSR 1998:I, p. 9, para. 45.
#2376904
Rialachán Cur Chun Feidhme (AE) 2021/1411 ón gCoimisiún an 27 Lúnasa 2021 maidir le hathnuachan a dhéanamh ar údarú Clostridium butyricum FERM BP-2789 mar bhreiseán beathaithe le haghaidh sicíní a thógtar le bheith ina mbéaróg, turcaithe lena ramhrú, turcaithe a thógtar le haghaidh pórúcháin, mionspeicis éanúla eile (seachas éin ubh-bhreithe), bainbh scoite agus mionspeicis mhucúla scoite, an t-údarú maidir le sicíní lena ramhrú, bainbh diúil agus mionspeicis mhucúla diúil, agus lena n-aisghairtear Rialacháin Cur Chun Feidhme (AE) Uimh. 373/2011, (AE) Uimh. 374/2013 agus (AE) Uimh. 1108/2014 (sealbhóir an údaraithe Miyarisan Pharmaceutical Co. Ltd atá á ionadú ag Huvepharma NV Belgium), tá sé le hionchorprú i gComhaontú LEE.
Commission Implementing Regulation (EU) 2021/1411 of 27 August 2021 concerning the renewal of the authorisation of Clostridium butyricum FERM BP-2789 as a feed additive for chickens reared for laying, turkeys for fattening, turkeys reared for breeding, minor avian species (excluding laying birds), weaned piglets and weaned minor porcine species, its authorisation for chickens for fattening, suckling piglets and suckling minor porcine species, and repealing Implementing Regulations (EU) No 373/2011, (EU) No 374/2013 and (EU) No 1108/2014 (holder of authorisation Miyarisan Pharmaceutical Co. Ltd represented by Huvepharma NV Belgium) is to be incorporated into the EEA Agreement.
#2376916
32021 R 1411: Rialachán Cur Chun Feidhme (AE) 2021/1411 ón gCoimisiún an 27 Lúnasa 2021 maidir le hathnuachan a dhéanamh ar údarú Clostridium butyricum FERM BP-2789 mar bhreiseán beathaithe le haghaidh sicíní a thógtar le bheith ina mbéaróg, turcaithe lena ramhrú, turcaithe a thógtar le haghaidh pórúcháin, mionspeicis éanúla eile (seachas éin ubh-bhreithe), bainbh scoite agus mionspeicis mhucúla scoite, an t-údarú maidir le sicíní lena ramhrú, bainbh diúil agus mionspeicis mhucúla diúil, agus lena n-aisghairtear Rialacháin Cur Chun Feidhme (AE) Uimh. 373/2011, (AE) Uimh. 374/2013 agus (AE) Uimh. 1108/2014 (sealbhóir an údaraithe Miyarisan Pharmaceutical Co. Ltd atá á ionadú ag Huvepharma NV Belgium) (IO L 304, 30.8.2021, lch. 11).
32021 R 1411: Commission Implementing Regulation (EU) 2021/1411 of 27 August 2021 concerning the renewal of the authorisation of Clostridium butyricum FERM BP-2789 as a feed additive for chickens reared for laying, turkeys for fattening, turkeys reared for breeding, minor avian species (excluding laying birds), weaned piglets and weaned minor porcine species, its authorisation for chickens for fattening, suckling piglets and suckling minor porcine species, and repealing Implementing Regulations (EU) No 373/2011, (EU) No 374/2013 and (EU) No 1108/2014 (holder of authorisation Miyarisan Pharmaceutical Co. Ltd represented by Huvepharma NV Belgium) (OJ L 304, 30.8.2021, p. 11).